Southwestern Energy Company, an independent energy company, engages
in the exploration, development, and production of natural gas and oil
primarily in the United States. The company operates through two
segments, Exploration and Production, and Midstream Services. The
Exploration and Production segment primarily focuses on the Fayetteville
Shale, an unconventional reservoir located in the Arkoma Basin in
Arkansas; and is involved in the exploration and production activities
in the Marcellus Shale play in Pennsylvania, as well as in Texas,
Arkansas, and Oklahoma. It also engages in exploration activities in the
Lower Smackover Brown Dense formation in Arkansas and Louisiana; the
Marmaton and Atoka formations in the Denver-Julesburg Basin in Colorado;
the Bakken and Three Forks formations in Montana; and in New Brunswick,
Canada, as well as operates drilling rigs in Arkansas, Pennsylvania,
and Louisiana. The Midstream Services segment provides natural gas
gathering, marketing, and transportation activities in Arkansas, Texas,
and Pennsylvania.
To review Southwestern's stock, please take a look at the 1-year
chart of SWN (Southwestern Energy Company) below with my added
notations:
SWN has been trading sideways for the last 8 months. Over that period
of time, the stock has formed a clear resistance level at $40 (red). In
addition, the stock has also created a strong level of support at $35
(blue) that has held since the end of April. At some point the stock
will have to break one of those two levels.
The Tale of the Tape: SWN has clear levels of
support ($35) and resistance ($40). The possible long positions on the
stock would be either on a pullback to $35, or on a breakout above $40.
The ideal short opportunity would be on a break below $35.
Please share this article
Friday, November 22, 2013
US Dollar ETF Trade Setup - UUP
We
all know quantitative easing devalues the Dollar but contrary to that
general statement it looks as though we could see the dollar index
continue to rise for a few more weeks.
If
we analyze the chart of the Dollar ETF (UUP) it is clear that the short
term momentum has turned up. The break above the down trend line and
recent bounce off support bodes well for the dollar index.
The
bull flag chart pattern that has formed in the past month has a
measured move price target of roughly $22.30. The level also happens to
be a key pivot point on the chart along with high volume resistance.
I
expect the dollar to continue to work its way higher over the next week
or two with $22.30 being the line in the sand where sellers will jump
on price and drive it back down, or at minimum force price to
consolidate for a few days.
US Dollar ETF Trading Strategy - Daily Chart Analysis
Economic Collapse ~ FED Taper Signals A Major Event Going Hot
The Gold Market has been smacked down and halted twice within 24 hours. The FED/central bankers are prepping the markets for a major event to take place. The FED minutes state that they are back the tapering track which might possibly happen in December 2013, or January 2014. This talk of taper is in preparation for the next false flag event. All the pieces to the puzzle are being put into place to stage the next horrific event.
Please share this article
Bankruptcy Looms For This BRIC Nation -- Here's What To Avoid: ILF, PBR, VALE
In early 1997, the world was in awe of the record growth of Southeast
Asia's "tiger economies" as markets opened and foreign investors rushed
to fund new ventures.
However, by January 1998, stock markets across the region had lost as much as 70% of their value, and the crisis had spread to the rest of the emerging world. Even behemoth Russia wasn't immune, defaulting on its debt that same year.
Such massive and rapid growth relied on a constant influx of dollars to fund deficits and pay higher amounts of foreign debt. At the first sign of economic cracks, foreign investors withdrew their accounts, leading to a plunge in currencies and leaving the region's governments unable to pay debt denominated in now more expensive dollars. (more)
Please share this article
However, by January 1998, stock markets across the region had lost as much as 70% of their value, and the crisis had spread to the rest of the emerging world. Even behemoth Russia wasn't immune, defaulting on its debt that same year.
Such massive and rapid growth relied on a constant influx of dollars to fund deficits and pay higher amounts of foreign debt. At the first sign of economic cracks, foreign investors withdrew their accounts, leading to a plunge in currencies and leaving the region's governments unable to pay debt denominated in now more expensive dollars. (more)
Please share this article
Dynavax Technologies (NASDAQ: DVAX): Could Make Traders 200%-Plus Profits
The first rule of running a biotech company: Don't run low on cash.
Once investors smell a cash squeeze coming, they'll hammer shares
mercilessly.
That was the painful lesson learned by the executives at Dynavax Technologies (NASDAQ: DVAX). Though DVAX was pursuing the development of a very promising new vaccine, the company was burning through more than $15 million in cash every quarter, and was at risk of not making it to the FDA finish line. Shares, which traded around $5 in October 2012, skidded all the way to $1.
The good news is that the company shored up its balance sheet late last month, and shares have finally begun to rebound. And, with a few breaks, DVAX looks poised to rise from a recent $1.45 to $3, $4 or even $5.
Little Company, Big Target Market
DVAX has spent years developing Heplisav, which is a vaccine for hepatitis B, a disease that currently afflicts 240 million people around the world, according to the World Health Organization. (more)
Please share this article
That was the painful lesson learned by the executives at Dynavax Technologies (NASDAQ: DVAX). Though DVAX was pursuing the development of a very promising new vaccine, the company was burning through more than $15 million in cash every quarter, and was at risk of not making it to the FDA finish line. Shares, which traded around $5 in October 2012, skidded all the way to $1.
The good news is that the company shored up its balance sheet late last month, and shares have finally begun to rebound. And, with a few breaks, DVAX looks poised to rise from a recent $1.45 to $3, $4 or even $5.
Little Company, Big Target Market
DVAX has spent years developing Heplisav, which is a vaccine for hepatitis B, a disease that currently afflicts 240 million people around the world, according to the World Health Organization. (more)
Please share this article
Subscribe to:
Posts (Atom)